This biomarker combination (TIMP-2 × IGFBP-7) is the only Food and Drug Administration-approved product for use in risk assessment for AKI in critically ill patients in the United States (NephroCheck) [29]. The gene discussed is TIMP2; the disease is acute kidney injury.